Table 1
Patient characteristics
| Patient | Sex | Age at onset of IU (years) | Age at onset of GA (years) | Follow up (years) | Bilateral IU | CMO | Vasculitis | Cataract | Glaucoma | Snow banking | Treatment of IU | Intraocular surgery (No of procedures) | Visual acuity at onset | Worst visual acuity | Optimal visual acuity | Cause of permanent visual loss | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CS = corticosteroids; NSAID = non-steroidal anti-inflammatory drug. | |||||||||||||||||||
| 1 | M | 8 | 5 | 7 | + | + | – | – | – | + | Periocular CS, topical NSAID | 0 | 0.02 | R | 0.02 | R | 0.1 | R | CMO |
| 1.25 | L | 1.25 | L | 0.25 | L | ||||||||||||||
| 2 | F | 50 | 55 | 8 | + | + | + | + | + | – | Systemic, periocular and topical CS, topical NSAID, acetazolamide | 2 | 1.0 | R | 1.0 | R | 1.0 | R | CMO |
| 0.2 | L | 0.2 | L | 0.6 | L | ||||||||||||||
| 3 | F | 23 | 22 | 1 | + | + | + | – | – | + | Periocular and topical CS, topical NSAID | 0 | 1.0 | R | 1.0 | R | 1.0 | R | – |
| 0.5 | L | 0.5 | L | 1.0 | L | ||||||||||||||
| 4 | M | 10 | 9 | 6.5 | + | + | + | + | + | + | Periocular and topical CS, topical NSAID | 3 | 1.0 | R | 0.02 | R | 1.0 | R | CMO |
| 0.4 | L | 0.2 | L | 0.8 | L | ||||||||||||||
| 5 | F | 36 | 38 | 7 | + | – | + | + | – | + | Systemic, periocular and topical CS, topical NSAID | 2 | 1.0 | R | 1.0 | R | 1.0 | R | vasculitis |
| 0.8 | L | 0.5 | L | 1.0 | L | ||||||||||||||
| 6 | F | 28 | 25 | 8 | + | – | + | + | + | – | Topical CS and topical NSAID | 0 | 1.0 | R | 0.6 | R | 0.6 | R | – |
| 1.0 | L | 0.4 | L | 0.8 | L | ||||||||||||||
| 7 | M | 60 | 62 | 2 | + | – | + | – | – | – | Topical CS | 0 | 0.4 | R | 0.4 | R | 0.8 | R | – |
| 0.5 | L | 0.5 | L | 0.8 | L | ||||||||||||||
| 8 | F | 9 | 25 | 17 | + | + | + | – | – | + | Systemic and periocular CS, systemic NSAID, acetazolamide | 0 | 0.4 | R | 0.4 | R | 0.8 | R | CMO |
| 1.0 | L | 1.0 | L | 1.25 | L | ||||||||||||||
